Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
talastine
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
Talastine is a second-generation alkylamine H1-antihistamine used for the treatment of allergic conditions such as allergic rhinitis and urticaria. It acts by selectively blocking the histamine H1 receptor, thereby inhibiting the effects of endogenous histamine and providing relief from allergy symptoms. Talastine is structurally classified as a phthalazinone derivative and belongs to the class of organic compounds known as diazanaphthalenes. Its antiallergic activity has been demonstrated in clinical studies, though it has also been reported to cause allergic drug exanthema in rare cases[1][3][5][8].
- Brand names
- AhanonAganon
- Other names
- talastine hydrochloride
02
Targets
HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on talastine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on talastine.